Cebranopadol's dual-NMR agonism could help manage pain by balancing analgesic efficacy and safety. The company anticipates sharing additional trial outcomes in the first quarter of this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback